Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GlaxoSmithKline Flovent HFA Clears FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

The CFC-free version of Flovent is approved for asthma in patients 12 years and older. The drug is the second HFA nasal steroid available.
Advertisement

Related Content

GlaxoSmithKline Discontinues Flovent Rotadisk
GlaxoSmithKline Discontinues Flovent Rotadisk
Albuterol MDI Essential Use Exemption To Be Discussed By Pulmonary Cmte.
CFC Proposed Rule Goes To OMB
Aventis CFC-Free Nasacort HFA Approved
Aventis CFC-Free Nasacort HFA Approved

Topics

Advertisement
UsernamePublicRestriction

Register

PS059416

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel